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Abstract
Aim: To identify clinical and/or genetic predictors of response to several therapies in Crohn’s disease (CD) patients.
Methods: We included 242 patients with CD (133 females) aged (mean standard deviation) 39 12 years and a disease
duration of 12 8 years. The single-nucleotide polymorphisms (SNPs) studied were ABCB1 C3435T and G2677T/A, IL23R
G1142A, C2370A, and G9T, CASP9 C93T, Fas G670A and LgC844T, and ATG16L1 A898G. Genotyping was performed with real-
time PCR with Taqman probes.
Results: Older patients responded better to 5-aminosalicylic acid (5-ASA) and to azathioprine (OR 1.07, p¼ 0.003 and OR
1.03, p¼ 0.01, respectively) while younger ones responded better to biologicals (OR 0.95, p¼ 0.06). Previous surgery
negatively influenced response to 5-ASA compounds (OR 0.25, p¼ 0.05), but favoured response to azathioprine (OR 2.1,
p¼ 0.04). In respect to genetic predictors, we observed that heterozygotes for ATGL16L1 SNP had a significantly higher
chance of responding to corticosteroids (OR 2.51, p¼ 0.04), while homozygotes for Casp9 C93T SNP had a lower chance of
responding both to corticosteroids and to azathioprine (OR 0.23, p¼ 0.03 and OR 0.08, p¼ 0.02,). TT carriers of ABCB1
C3435T SNP had a higher chance of responding to azathioprine (OR 2.38, p¼ 0.01), while carriers of ABCB1 G2677T/A SNP, as
well as responding better to azathioprine (OR 1.89, p¼ 0.07), had a lower chance of responding to biologicals (OR 0.31,
p¼ 0.07), which became significant after adjusting for gender (OR 0.75, p¼ 0.005).
Conclusions: In the present study, we were able to identify a number of clinical and genetic predictors of response to several
therapies which may become of potential utility in clinical practice. These are preliminary results that need to be replicated
in future pharmacogenomic studies.
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Introduction
Crohn’s disease (CD) is a chronic and relapsing condi-
tion, with the majority of patients experiencing a pro-
gressive and disabling course over time.1,2 Management
of disease is complex and should take into account sev-
eral factors such as disease location, activity, and behav-
iour.3 Additional disease aspects thatmakemanagement
diﬃcult are the lack of correlation between severity of
clinical symptoms and severity of intestinal inﬂamma-
tion and the diﬃculty in predicting a patient’s clinical
course and the individual response to a given treatment.
According to ECCO guidelines, 5-aminosalicylic
acid (5-ASA) compounds could be used to treat
patients with mild-to-moderate ileocecal disease,
whereas the use of azathioprine/6-mercaptopurine
and/or anti-tumour necrosis factor (TNF) therapy is
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recommended for patients with moderate to severe dis-
ease who relapse after responding to steroids.3
In the past years, numerous eﬀorts have been made
with the aim of identifying early predictors of aggres-
sive disease4–6 because, intuitively, patients presenting
indicators of bad outcome at diagnosis would be the
ideal candidates for early and more aggressive therapy
in order to avoid long-term structural damage.
However, patients who present with disease bad prog-
nostic factors are not necessarily those who will
respond better or worse to certain therapies.
Although tailored therapy in CD is still far from reality,
reliable prediction of response to treatment, combined
with clinical indicators of aggressive disease, could
allow a better selection of candidates for treatment,
allowing the choise of not only the most eﬀective thera-
pies but also the less toxic ones. It is certainly important
to remember that, according to previous studies,7,8
30% of CD patients will have a mild disease course
and will never need corticosteroids.
Previous studies have mainly focused on clinical pre-
dictors of response to biologicals. Short duration of dis-
ease is probably the single most important factor of
response to anti-TNF agents and perhaps to azathiopr-
ine as well.9–11 Some found better responses to bio-
logicals in nonsmoking patients with recent onset and
colonic disease, while others could not conﬁrm these
observations.12–15 A high value of basal C-reactive pro-
tein also seems to be a predictive factor of response to
biologicals.16
As well as clinical and laboratory predictors, gen-
etics could also inﬂuence patients’ individual response
to a drug.17,18 So far, pharmacogenomic research in
inﬂammatory bowel disease has witnessed only
modest success and sometimes conﬂicting results,
mainly because response to treatment in this disease is
very heterogeneous as it is inﬂuenced by many factors,
such as disease duration, behaviour, and severity, which
certainly interact with genetic variables and modulate
response to treatment.19–21 While some authors
reported that carriers of ABCB1 single-nucleotide poly-
morphisms (SNPs) present a worse response to
azathioprine or corticosteroids, others could not con-
ﬁrm these observations.22–25 ABCB1 codes for the
ATP-dependent membrane eﬄux transporter P-glyco-
protein 1, which is expressed in various cells including
in those in the gastrointestinal tract, which is respon-
sible for resistance to a number of structurally and
functionally unrelated drugs. IL23R has been recently
implicated in the pathogenesis of CD. Although previ-
ous studies found that SNPs in this gene could increase
susceptibility to develop CD,26 few studies explored the
association between these SNPs and phenotype or
response to therapy in patients with inﬂammatory
bowel disease.18,27,28 Caspase9, Fas, and fas ligand
encode for proteins involved in apoptosis, which has
been shown to be defective in CD. Hlavaty et al.29,30
observed that carriers of SNPs of genes involved in
apoptosis, responded less frequently to biologicals.
Finally, ATG16L1 is involved in autophagy, a key
pathway for innate immunity and important for main-
taining the epithelial barrier. Several drugs already used
in the treatment of CD might exert at least part of their
eﬀect through the regulation of autophagy.31 A recently
published study found an association between SNPs in
this gene and response to corticosteroids, azathioprine,
and biologicals.32
The primary aim of the present study was to identify
clinical and/or genetic factors that, alone or in combin-
ation, could predict response of CD patients to several
therapies. Our secondary end point was to distinguish
between those patients who will be in remission with
azathioprine only from those who will need escalation
to anti-TNF agents.
Materials and methods
This was a multicentre study with participating hos-
pitals from Central Portugal. Informed consent was
obtained from all patients entering the study, which
was approved by Scientiﬁc and Ethical committees of
the several participating hospitals.
Patients with the diagnosis of CD33 were classiﬁed
according to the Montreal classiﬁcation34 based on age
at diagnosis (A), location (L), and behaviour (B).
Disease modiﬁers were also considered: L4 when the
upper digestive tract was involved and P for perianal
involvement. No families with CD were included in the
present series. Phenotypic characteristics retrospect-
ively collected from charts included demographic
data, age of disease onset, disease extension, and behav-
iour, time of follow up, smoking habits, presence of
extraintestinal manifestations, and previous therapies
including surgery. All phenotypic data were collected
in a blinded fashion to the results of the genotypic data.
Patients were selected to enter the study if a deﬁni-
tive classiﬁcation in terms of response to a speciﬁc drug
could be clearly obtained after reviewing the chart and
interviewing the patient at the moment of entering the
study. Patients were considered responders if they pre-
sented long-term sustained remission, deﬁned as a
Harvey Bradshaw Index (HBI) lower than 4, lasting
at least 1 year after a certain therapy was started, not
needing steroids, surgery, or escalation of therapy to
biologicals for those taking azathioprine or switch to
another biological (inﬂiximab vs. adalimumab) for
those on biologicals. Patients requiring the addition
or switching to other therapies, corticosteroids or sur-
gery before 1 year were considered nonresponders. If a
clear distinction between these two scenarios was not
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possible for a speciﬁc drug, the patient was not con-
sidered either as a responder or as a nonresponder at
least for this drug. Because our secondary end point
was to distinguish between patients who responded to
azathioprine from those who came to require bio-
logicals, if a patient had a clinical remission for less
than 1 year with azathioprine but came to require bio-
logicals, he or she was considered a nonresponder to
azathioprine.
Decision to switch therapy was made by the treating
physician. HBI was calculated after a new therapy was
started until the drug was discontinued or until end of
follow up. Optimization of dose and/or interval of
administration in patients on biologicals, was con-
sidered as therapy optimization and not as nonre-
sponse. Biological parameters such as C-reactive
protein levels or endoscopic response were not used
to classify patients as responders or nonresponders
because identiﬁcation of these data on the precise
moment on which a speciﬁc therapy was started was
not clear in a large number of patients.
For steroids, only short-term response was con-
sidered. Steroid dependence was deﬁned as recurrent
ﬂare up on withdrawal of glucocorticoids or as the
need for glucocorticoids treatment twice within 6
months. Patients were considered refractory to steroids
when no remission was obtained with a dose of 1mg/kg
during a period of at least 4 weeks.
DNA extraction and genotyping
Blood samples were taken from all study participants,
and genomic DNA was isolated from peripheral blood
using a DNA blood mini kit from Quiagen (Hiden,
Germany) according to the manufacturer’s guidelines.
A total of 10 SNPs were studied: ABCB1 C3435T
(rs1045642) and G2677T/A (rs2032582), IL23R
G1142A (rs11209026), C2370A (rs10889677),
G43045A (rs 1004819) and G9T (rs1884444), CASP9
C93T (rs4645983), Fas G670A (rs1800682), Faslg
C844T (rs763110), and ATG16L1 A898G (rs2241880).
All genotypes were determined using real-time PCR
with TaqMan Pre-Designed SNP Genotyping Assays
(Applied Biosystems, USA), except for Fas G670A
and FasLg C844TT, which were determined using
Custom TaqMan SNP genotyping Assays probes
(Applied Biosystems). To perform the genotype ana-
lysis, the target fragments were ampliﬁed in 20 -ml reac-
tion mixture containing 10 ml TaqMan Universal PCR
Master Mix, 1 ml primers, 5 ml Milli-Q water, and 4 ml
DNA. Real-time PCR was conducted using a iCycler
iQ Multicolor Real-Time PCR Detection System
(BIO-RAD) with the following thermal cycling pro-
gram: 10min at 95C and 50 cycles of 15 s at 92C
and 1min at 60C.
Statistical analysis
Statistical analysis was performed using SPSS version
14.0 (SPSS, Chicago, IL, USA) and SNPassoc 1.6 pack-
age in R software. Data were expressed as
mean standard deviation, number of subjects (%),
or odds ratio (OR) with 95% conﬁdence interval (CI).
Primary analyses were performed using chi-squared test
and univariate logistic regression. Multivariate logistic
regression was performed to adjust for potential con-
founding variables. Receiver operating characteristic
(ROC) curves were plotted for multivariate models,
and sensitivity, speciﬁcity, positive predictive value
(PPV), negative predictive value (NPV), and area
under the curve (AUC) were calculated. Whenever the
AUC value was under 0.65, the model performance was
considered unacceptably low and data are not shown.
Association between outcome and SNP was analysed
with SNPassoc library in R and SPSS 19 (IBM SPSS
statistics). Diﬀerent inheritance models (dominant,
recessive, log-add, and overdominant) were considered
and were presented as eligible. Haplotype analysis was
performed for ABCB1 C3435T and ABCB1 G2677T/A.
To adjust for multiple testing, a Bonferroni correction
was applied. Statistical signiﬁcance was established for
p< 0.05. Diﬀerences in genotypic and allelic frequen-
cies and Hardy–Weinberg tests were performed using
GENEPOP Web version 4.0.10 program. To obtain the
exact p-value of the Hardy–Weinberg equilibrium, the
Markov Chain method (Guo and Thompson, 1992)
with a dememorization number of 1000, 100 batches,
and 1000 iterations per batch was used. The p-value
returned by this method is calculated as the sum of
the probabilities of all tables and its standard error.
Genotypic frequencies are under Hardy–Weinberg
equilibrium when p> 0.001
Results
A total of 242 CD patients were eligible to enter the
study; mean follow-up period was 2.5 years. There were
no patients treated according to the top-down strategy.
Because the criteria used to consider patients as respon-
ders or nonresponders required sustained clinical remis-
sion for 1 year or more, there were only four patients
who were considered responders simultaneously to
azathioprine and biologicals. The demographic, clin-
ical, and response to therapy data are shown on
Table 1.
Allelic and genotypic frequencies
Allelic and genotypic frequencies for all the studied
SNPs are shown in Table 2. The genotypic frequencies
of all SNPs did not deviate signiﬁcantly from those
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Table 1. Demographic and clinical data from patients included in
the study
Characteristic
Study population
(n¼ 242)
Gender
Male 109 (45)
Female 133 (55)
Age (years) 39 12.8
Duration of disease (years) 11.8 8.4
Duration of follow up (years) 2.5 3.2
Age of disease onset
A1 28 (12)
A2 183 (75)
A3 31 (13)
Location of disease
L1 54 (22)
L2 48 (20)
L3 140 (58)
L4 20 (8)
Behaviour of disease
B1 110 (45)
B2 93 (39)
B3 39 (16)
Perianal involvement 90 (39)
Previous surgery
Yes 64 (26)
No 178 (74)
Perianal procedures 38 (16)
Smoking habits
Yes 66 (27)
No 141 (58)
Unknown 35 (14)
Extraintestinal manifestations
Yes 79 (33)
No 163 (67)
5-Aminosalicylic acid
Yes 29 (48/12)
No 31 (52)
Corticosteroids
Yes 107 (74/44)
No 37 (26)a
Azathioprine
Yes 90 (56/41)
No 70 (44)
Biologicals
Yes 81 (81/33)
No 19 (19)
Values are n (%), mean standard deviation, or % responders to drug/%
responders of total.
aResponse to corticosteroids refers to short-term (1 month) response. Of
these 37 patients, seven were refractory to corticosteroids and 30 were
corticodependent.
Table 2. Genotypic frequencies, allelic frequencies, and Hardy–
Weinberg equilibrium
Polymorphism Genotypes Alleles
Hardy–
Weinberg
equilibrium
ABCB1 C3435T
CC (n¼ 71) 0.298
CT (n¼ 100) 0.420 C 0.508
TT (n¼ 67) 0.282 T 0.492 p¼ 0.0147
ABCB1 G2677T/A
GG (n¼ 66) 0.282
GTþGA (n¼ 119) 0.517 G 0.527
TTþAAþTA (n¼ 53) 0.202 T/A 0.473 p¼ 1.0000
IL23R G1142A
GG (n¼ 193) 0.801
GA (n¼ 47) 0.195 G 0.898
AA (n¼ 1) 0.400 A 0.102 p¼ 0.4826
IL23R C2370A
CC (n¼ 93) 0.389
CA (n¼ 114) 0.477 C 0.628
AA (n¼ 32) 0.134 A 0.372 p¼ 0.8902
IL23R G9T
TT (n¼ 58) 0.244
TG (n¼ 119) 0.500 T 0.494
GG (n¼ 61) 0.256 G 0.506 p¼ 1.0000
IL23R C/T
CC (n¼ 83) 0.353
CT (n¼ 123) 0.523 C 0.615
TT (n¼ 29) 0.123 T 0.385 p¼ 0.1353
Casp9 C93T
CC (n¼ 131) 0.567
CT (n¼ 86) 0.372 C 0.753
TT (n¼ 29) 0.610 T 0.247 p¼ 1.0000
Fas G670A
GG (n¼ 44) 0.191
GA (n¼ 120) 0.522 G 0.452
AA (n¼ 66) 0.287 A 0.548 p¼ 0.5047
Fas LgC844T
CC (n¼ 73) 0.319
CT (n¼ 104) 0.454 C 0.546
TT (n¼ 52) 0.227 T 0.454 p¼ 0.2317
ATG16L1 A898G
AA (n¼ 43) 0.297
AG (n¼ 100) 0.437 A 0.406
GG (n¼ 86) 0.266 G 0.594 p¼ 0.1750
There was no deviation from Hardy–Weinberg equilibrium.
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expected under Hardy–Weinberg equilibrium
(p> 0.001).
Associations between genetic polymorphisms and
phenotypic characteristics
We observed that carriers for IL23R G9T and IL23R
C2370A SNPs had less frequently upper GI involve-
ment as compared to wild-type carriers (OR 0.4, 95%
CI 0.2–0.82, p¼ 0.008, and OR 0.25, 95% CI 0.06–0.86,
p¼ 0.03, respectively). Also, TT carriers for FasLg
C844T SNP exhibited more often an inﬂammatory
behaviour (B1) (OR 0.38, 95% CI 0.18–0.82,
p¼ 0.014). No other signiﬁcant associations were
observed between the remaining SNPs and disease
characteristics.
Associations between clinical characteristics,
SNPs, and response to therapy
An analysis of associations between clinical variables
and response to several drugs according to univariate
analysis was performed. Only signiﬁcant or near signiﬁ-
cant associations are displayed in Table 3.
We observed that older patients and those with a
longer duration of disease responded better to 5-ASA
compounds (OR 1.07, p¼ 0.003 and OR 1.16,
p¼ 0.002, respectively). On multivariate analysis, after
adjusting for age and previous surgery, disease duration
remained statistically signiﬁcant (OR 1.21, p¼ 0.005);
however, age was no longer statistically signiﬁcant.
The same trend was observed in respect to response
to azathioprine and age (OR 1.03, p¼ 0.01), which
means that there is a 3% increase in the chance of
responding to azathioprine for each additional year of
life. In respect to biologicals, an opposite trend was
observed with a higher chance of response in younger
patients (p¼ 0.06) and with more recent disease onset
(p¼ 0.008). However, on multivariate analysis, both
age and duration of disease lost signiﬁcance.
Previous surgery negatively inﬂuenced response to
5-ASA compounds (OR 0.25, p¼ 0.05), while the
opposite eﬀect was observed in regard to azathioprine
(OR 2.1, p¼ 0.04) (Table 3). In respect to perianal
involvement, we observed that these patients did signiﬁ-
cantly worse on corticosteroids (OR 0.32, p¼ 0.006)
(Table 3). No signiﬁcant associations were found
between disease behaviour, disease location including
L4 involvement, smoking habits, presence of extrain-
testinal manifestations, and response to various thera-
pies. Stricturing and penetrating phenotypes (B2 and
B3, respectively) were more often associated with sur-
gical therapy in contrast with inﬂammatory phenotype
(B1) (OR 18.3, 95% CI 7.5–54.8, p< 0.0001).
Interestingly, previous therapies seemed to inﬂuence
response to therapy in various ways (Table 3). Thus,
previous 5-ASA users responded better to biologicals,
although not reaching statistical signiﬁcance (OR 2.86,
95% CI 0.90–8.94, p¼ 0.06). Previous corticosteroid
therapy negatively inﬂuenced response to 5-ASA (OR
0.05, 95% CI 0.003–0.333, p¼ 0.008). Finally, previous
use of biologicals decreased the chance of responding
Table 3. Association between clinical phenotypic characteristics and response to therapy according to univariate analysis
Characteristic 5-ASA (n¼ 60)
Corticosteroids
(n¼ 144)
Azathioprine
(n¼ 160)
Biologicals
(n¼ 100)
Responders/nonresponders 29/31 107/37 90/70 81/19
Age 1.07 (1.02–1.14)
p¼ 0.003
– 1.03 (1.006–1.06)
p¼ 0.01
0.95 (0.90–1.00)
p¼ 0.06
Duration of disease 1.16 (1.07–1.31)
p¼ 0.002
– – 0.91 (0.85–0.98)
p¼ 0.008
Previous surgery 0.25 (0.05–0.96)
p¼ 0.05
– 2.1 (1.04–4.49)
p¼ 0.04
–
Perianal disease – 0.32 (0.14–0.72)
p¼ 0.006
– –
Previous 5-ASA – – – 2.86 (0.90–8.94)
p¼ 0.06
Previous steroids 0.05 (0.03–0.33)
p¼ 0.008
– – –
Previous biologicals – 0.26 (0.11–0.60)
p¼ 0.002
0.05 (0.02–0.13)
p¼ 1.26 10–9
–
Values are OR (95% CI). OR< 1.00, less responsive; OR> 1.00, better response. Table only displays significant or near significant results.
5-ASA, 5-Aminosalicylic acid.
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both to corticosteroids (OR 0.26, p¼ 0.002) and to
azathioprine (OR 0.05, p¼ 1.26 10–9).
The associations between genetic polymorphisms
and response to therapy on univariate analysis are
shown on Table 4. We observed that heterozygotes
for the polymorphic allele of IL23R G9T had a lower
chance of responding to 5-ASA compounds (OR 0.29,
p¼ 0.06) but a higher one of responding to biologicals
(OR 3.06, p¼ 0.06).
Homozygotes for Casp9 C93T SNP had a signiﬁ-
cantly lower chance of responding both to corticoster-
oids and to azathioprine (OR 0.23, p¼ 0.03 and OR
0.08, p¼ 0.02, respectively; Table 4). After adjusting
for previous response to biologicals, gender, and
ATGL16L1, the probability of responding to cortico-
steroids was even further decreased (OR 0.14, 95% CI
0.03–0.71 p¼ 0.014). A ROC curve was plotted for the
previous model: 71.1% sensibility, 71.9% speciﬁcity,
54.9% PPV, 11.5% NPV, and an AUC of 0.778 was
obtained (Figure 1).
In respect to the ABCB1 C3435T SNP, we observed
that TT carriers had a signiﬁcantly higher chance of
responding to azathioprine (OR 2.38, p¼ 0.01;
Table 4). After adjusting for gender distribution, we
observed that this association remained signiﬁcant
(OR 2.4, 95% CI 1.13–5.03 p¼ 0.019) and became
even more signiﬁcant after further adjustment for age
and smoking habits (OR 3.22, 95% CI 1.13–5.03
p¼ 0.005). Model assessment with a ROC curve gener-
ated a 60,5% sensibility, 73% speciﬁcity, 39.5% PPV,
27% NPV, and an AUC of 0.687 (Figure 2).
The same was observed for the polymorphic allele
carriers of the other SNP of this gene (ABCB1 G2677T/
A), although not reaching statistical signiﬁcance (OR
1.89, p¼ 0.07). Carriers of both haplotypes had a
higher chance of responding to azathioprine (OR
1.53, 95% CI 0.94–2.49, p¼ 0.08). The ABCB1
G2677T/A SNP, as well as responding better to
azathioprine, had a signiﬁcantly lower chance of
responding to biologicals (OR 0.31, p¼ 0.07), which
became signiﬁcant after adjusting for gender (OR
0.75, 95% CI 0.24–0.63, p¼ 0.005). Adjusting for dur-
ation of disease also increased the strength of this asso-
ciation (OR 0.23, 95% CI 0.07–0.70, p¼ 0.01). When
considering the ROC curve for the former model,
70.1% sensibility, 63.2% speciﬁcity, 65.7% PPV,
11.5% NPV, and an AUC of 0.714 was obtained
(Figure 3).
We also examined whether there was any interaction
between clinical and genetic predictors of response. As
shown in Table 5, we observed that carriers for both
ABCB1 SNPs responded better to azathioprine only if
Table 4. Association between genetic polymorphism and response to therapy according to univariate analysis
Polymorphism and genotype
5-ASA
(n¼ 60)
Corticosteroids
(n¼ 144)
Azathioprine
(n¼ 160)
Biologicals
(n¼ 100)
Responders/nonresponders 29/31 107/37 90/70 81/19
IL23R G9T: GT 0.29 (0.08–1.03)
p¼ 0.06
– – 3.06 (0.91–10.4)
p¼ 0.06
Casp9 C93T: TT – 0.23 (0.36–0.88)
p¼ 0.03
0.08 (0.004–0.51)
p¼ 0.02
–
ABCB1 C3435T: TT – – 2.38 (1.13–5.02)
p¼ 0.01
–
ABCB1 G2677T/A: TT vs. G carrier – – 1.89 (0.94–3.81)
p¼ 0.07
0.31 (0.08–1.07)
p¼ 0.07
Values are OR (95% CI). OR< 1.00, less responsive; OR> 1.00, better response. Table only displays significant or near significant results.
5-ASA, 5-Aminosalicylic acid.
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Figure 1. Receiver operating characteristic curve for model
assessment of the Casp9 C93T SNP
Multivariate logistic regression model: dependent variable, therapy
response to corticosteroids; independent variables, Casp9 C93T
SNP, gender, previous therapy with infliximab, and ATGL16L1.
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they had an ileocolonic involvement as compared to
isolated ileal or colonic disease.
Discussion
CD is a heterogeneous disease both in terms of clinical
manifestations as well as in terms of response to
therapy. Great eﬀort has been dedicated to develop
treatment algorithms with the aim of choosing the
most eﬀective treatment with less adverse eﬀects and
risks.35–39 In this sense, a number of previous studies
tried to identify clinical,12–16,40 serological,41,42 or gen-
etic17–25 predictors of response to several therapies
available; however, so far, the results have not been
very consistent across studies. One of the reasons for
these discrepancies might result from what is con-
sidered response. In the present study, we decided to
use long-term response (more than 1 year) because we
believe that this concept is clinically more relevant.
Thus, a patient who responds to azathioprine or bio-
logicals at 2–3 months but later relapses with the need
of corticosteroids or escalation of therapy was con-
sidered a nonresponder to this speciﬁc therapy.
In regard to predictors of response, we used both
clinical and genetic markers. The latter may be more
attractive because they do not change over time.
However, in clinical practice they are of little value
until their utility can be clearly demonstrated and vali-
dated in other studies. In contrast, clinical or pheno-
typic variables are more readily used in clinical practice.
In the present study, 25% of patients (60/242) were
treated with 5-ASA: 29 of these responded to this ther-
apy whereas the remaining 31 did not and required fur-
ther escalation of therapy. Although overall this means
a low number of patients (29/242, 12%), we think that
it is certainly important to identify those patients who
do very well on less aggressive and less toxic therapies.
According to the last ECCO consensus,3 no treatment
may be an option in patients with mild disease, because
a systematic review of clinical trials43 showed that 18%
of patients (95% CI 14–24%) of patients entered remis-
sion with placebo alone. In line with these ﬁndings, it is
plausible that these patients could be treated with
5-ASA compounds only.
Previous surgery was a negative predictor of
response in regard to 5-ASA (OR 0.25), but previously
operated patients had a twice-higher chance of
responding to azathioprine (OR 2.1). Clinically, we
are often faced with the patient who does not respond
to medical therapy, needs surgery, and post operatively
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Multivariate logistic regression model: dependent variable, therapy
response to azathioprine; independent variables, ABCB1 C3435T
SNP, gender, smoking habits, and age.
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Figure 3. Receiver operating characteristic curve for model
assessment of the ABCB1 G2677T/A SNP
Multivariate logistic regression model: dependent variable, therapy
response to biologics; independent variables, ABCB1 G2677T/A
SNP, gender, and disease duration.
Table 5. Interaction between ABCB1 haplotypes (C3435T and
G2677T/A) and disease location
Haplotype
Ileal
disease (L1)
Colonic
disease (L2)
Ileocolonic
disease (L3)
CG 1.00 1.00 1.00
TG 0.57 (0.11–3.10) 0.28 (0.02–3.63) 3.51 (1.02–11.99)*
CT 1.45 (0.17–12.07) 0.00 5.9 (1.28–22.19)*
TT 2.05 (0.62–6.43) 1.18 (0.40–3.52) 2.0 (0.98–4.09)
*p¼ 0.01.
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has a mild course, further raising the question of
whether, once the diseased segment is resected, he can
be maintained on 5-ASA therapy or whether immuno-
suppression should be started. Our data strongly sup-
ports the latter.
In regard to corticosteroids we observed that previ-
ous therapy with biologicals was a negative predictor of
response to both corticosteroids (OR 0.26) and to
azathioprine (OR 0.05). These are important observa-
tions from a clinical point of view because patients who
are on biologicals and relapse are often treated with
corticosteroids.3 According to our results, this is not
contraindicated but they are less likely to respond.
Also, patients who are doing well on combination ther-
apy and in whom we want to de-escalate therapy, the
immunosuppressor (azathioprine) should preferentially
be stopped.
Genetic polymorphisms included in the present
study were chosen according to previous studies,
which had shown some type of association with
response to therapy. Although some previously
reported associations could not be conﬁrmed in the
present study,23,29,30 we found some interesting associ-
ations in the sense that genotypes identiﬁed patients
who were simultaneously less likely to respond to cer-
tain therapies but more prone to respond to others.
Thus, individuals who are heterozygotic for IL23R
G9T SNP were less likely to respond to 5-ASA (OR
0.29) but 3-times more likely to respond to biologicals
(OR 3.06). TT carriers of Casp9 C93T SNP had a sig-
niﬁcant reduction in the probability of responding both
to corticosteroids and azathioprine (OR 0.23 and 0.08,
respectively), while TT carriers for both ABCB1
C3435T and ABCB1 G2677T/A showed a higher
chance of responding to azathioprine. Concomitantly,
TT carriers for ABCB1 G2677T/A had a 25% reduc-
tion in the probability of responding to biologicals,
which might be relevant in clinical decisions. ROC
curves were plotted to test the performance of each of
these models. This analysis allowed us to assess the
performance of each of these models including SNPs
for the several genetic associations found in multivari-
ate analysis and response to corticosteroids, azathiopr-
ine, and biologicals. AUC values close or higher than
0.70 are considered reasonable classiﬁers, further rein-
forcing the reliability of the associations found between
SNPs tested and response to several therapies.
This study had some limitations that need to be
addressed. A major drawback relies on the fact that
response to drugs was evaluated retrospectively from
data recorded in the charts. However, in our opinion,
after having the perspective of long-term evolution and
whether the patient came to require therapy escalation
after a transitory response which lasted less than 1 year,
evaluating the response to a speciﬁc drug is clinically
more relevant than evaluating short-term responses.
Another limitation refers to the number of patients
included in the study, which may be considered low
for a pharmacogenomic study. Therefore, the data
obtained in the present study can only be considered
preliminary until prospectively validated in an inde-
pendent cohort of CD patients.
In conclusion, in the present study we were able to
identify a number of clinical predictors of response to
several therapies available to treat CD patients, that
might be of help in clinical practice, not only to select
patients for more potent therapies such as immunosup-
pressors or biologicals, but also to less toxic ones such
as 5-ASA compounds. In regard to genetic predictors,
associations found are certainly promising but can
only, at best, be considered hypothesis generating
until these results are conﬁrmed in larger populations.
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